Cargando…

Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013

OBJECTIVE: Guidelines for muscle-invasive bladder cancer (MIBC) recommend that patients receive neoadjuvant chemotherapy with radical cystectomy as treatment over radical cystectomy alone. Though trends and practice patterns of MIBC have been defined using the National Cancer Database, data using th...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalfant, Victor, Blute, Michael L., Silberstein, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875153/
https://www.ncbi.nlm.nih.gov/pubmed/36721688
http://dx.doi.org/10.1016/j.ajur.2021.10.002
_version_ 1784877900411961344
author Chalfant, Victor
Blute, Michael L.
Silberstein, Peter
author_facet Chalfant, Victor
Blute, Michael L.
Silberstein, Peter
author_sort Chalfant, Victor
collection PubMed
description OBJECTIVE: Guidelines for muscle-invasive bladder cancer (MIBC) recommend that patients receive neoadjuvant chemotherapy with radical cystectomy as treatment over radical cystectomy alone. Though trends and practice patterns of MIBC have been defined using the National Cancer Database, data using the Surveillance, Epidemiology, and End Results (SEER) program have been poorly described. METHODS: Using the SEER database, we collected data of MIBC according to the American Joint Commission on Cancer. We considered differences in patient demographics and tumor characteristics based on three treatment groups: chemotherapy (both adjuvant and neoadjuvant) with radical cystectomy, radical cystectomy, and chemoradiotherapy. Multinomial logistic regression was performed to compare likelihood ratios. Temporal trends were included for each treatment group. Kaplan-Meier curves were performed to compare cause-specific survival. A Cox proportional-hazards model was utilized to describe predictors of survival. RESULTS: Of 16 728 patients, 10 468 patients received radical cystectomy alone, 3236 received chemotherapy with radical cystectomy, and 3024 received chemoradiotherapy. Patients who received chemoradiotherapy over radical cystectomy were older and more likely to be African American; stage III patients tended to be divorced. Patients who received chemotherapy with radical cystectomy tended to be males; stage II patients were less likely to be Asian than Caucasian. Stage III patients were less likely to receive chemoradiotherapy as a treatment option than stage II. Chemotherapy with radical cystectomy and chemoradiotherapy are both underutilized treatment options, though increasingly utilized. Kaplan-Meier survival curves showed significant differences between stage II and III tumors at each interval. A Cox proportional-hazards model showed differences in gender, tumor stage, treatment modality, age, and marital status. CONCLUSION: Radical cystectomy alone is still the most commonly used treatment for muscle-invasive bladder cancer based on temporal trends. Significant disparities exist in those who receive radical cystectomy over chemoradiotherapy for treatment.
format Online
Article
Text
id pubmed-9875153
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Second Military Medical University
record_format MEDLINE/PubMed
spelling pubmed-98751532023-01-30 Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013 Chalfant, Victor Blute, Michael L. Silberstein, Peter Asian J Urol Original Article OBJECTIVE: Guidelines for muscle-invasive bladder cancer (MIBC) recommend that patients receive neoadjuvant chemotherapy with radical cystectomy as treatment over radical cystectomy alone. Though trends and practice patterns of MIBC have been defined using the National Cancer Database, data using the Surveillance, Epidemiology, and End Results (SEER) program have been poorly described. METHODS: Using the SEER database, we collected data of MIBC according to the American Joint Commission on Cancer. We considered differences in patient demographics and tumor characteristics based on three treatment groups: chemotherapy (both adjuvant and neoadjuvant) with radical cystectomy, radical cystectomy, and chemoradiotherapy. Multinomial logistic regression was performed to compare likelihood ratios. Temporal trends were included for each treatment group. Kaplan-Meier curves were performed to compare cause-specific survival. A Cox proportional-hazards model was utilized to describe predictors of survival. RESULTS: Of 16 728 patients, 10 468 patients received radical cystectomy alone, 3236 received chemotherapy with radical cystectomy, and 3024 received chemoradiotherapy. Patients who received chemoradiotherapy over radical cystectomy were older and more likely to be African American; stage III patients tended to be divorced. Patients who received chemotherapy with radical cystectomy tended to be males; stage II patients were less likely to be Asian than Caucasian. Stage III patients were less likely to receive chemoradiotherapy as a treatment option than stage II. Chemotherapy with radical cystectomy and chemoradiotherapy are both underutilized treatment options, though increasingly utilized. Kaplan-Meier survival curves showed significant differences between stage II and III tumors at each interval. A Cox proportional-hazards model showed differences in gender, tumor stage, treatment modality, age, and marital status. CONCLUSION: Radical cystectomy alone is still the most commonly used treatment for muscle-invasive bladder cancer based on temporal trends. Significant disparities exist in those who receive radical cystectomy over chemoradiotherapy for treatment. Second Military Medical University 2023-01 2021-11-02 /pmc/articles/PMC9875153/ /pubmed/36721688 http://dx.doi.org/10.1016/j.ajur.2021.10.002 Text en © 2021 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Chalfant, Victor
Blute, Michael L.
Silberstein, Peter
Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013
title Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013
title_full Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013
title_fullStr Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013
title_full_unstemmed Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013
title_short Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013
title_sort treatment trends of muscle invasive bladder cancer: evidence from the surveillance, epidemiology, and end results database, 1988 to 2013
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875153/
https://www.ncbi.nlm.nih.gov/pubmed/36721688
http://dx.doi.org/10.1016/j.ajur.2021.10.002
work_keys_str_mv AT chalfantvictor treatmenttrendsofmuscleinvasivebladdercancerevidencefromthesurveillanceepidemiologyandendresultsdatabase1988to2013
AT blutemichaell treatmenttrendsofmuscleinvasivebladdercancerevidencefromthesurveillanceepidemiologyandendresultsdatabase1988to2013
AT silbersteinpeter treatmenttrendsofmuscleinvasivebladdercancerevidencefromthesurveillanceepidemiologyandendresultsdatabase1988to2013